Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-90009530 |
Synonyms | |
Therapy Description |
Limited information is currently available on JNJ-90009530, a putative chimeric antigen receptor (CAR) T cell therapy targeting MS4A1 (CD20) (Nov 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-90009530 | JNJ 90009530|JNJ90009530 | CD20 Immune Cell Therapy 11 | Limited information is currently available on JNJ-90009530, a putative chimeric antigen receptor (CAR) T cell therapy targeting MS4A1 (CD20) (Nov 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05784441 | Phase I | JNJ-90009530 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | Recruiting | USA | ISR | GBR | AUS | 0 |